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Hepatitis C virus (HCV) infects cells by the direct uptake of cell-free virus following virus
engagement with specific cell receptors such as CD81. Recent data have shown that HCV is also
capable of direct cell-to-cell transmission, although the role of CD81 in this process is disputed.
Here, we generated cell culture infectious strain JFH1 HCV (HCVcc) genomes carrying an alanine
substitution of E2 residues W529 or D535 that are critical for binding to CD81 and infectivity.
Co-cultivation of these cells with naı ¨ve cells expressing enhanced green fluorescent protein
(EGFP) resulted in a small number of cells co-expressing both EGFP and HCV NS5A, showing
that the HCVcc mutants are capable of cell-to-cell spread. In contrast, no cell-to-cell transmission
from JFH1DE1E2-transfected cells occurred, indicating that the HCV glycoproteins are essential
for this process. The frequency of cell-to-cell transmission of JFH1W529A was unaffected by the
presence of neutralizing antibodies that inhibit E2–CD81 interactions. By using cell lines that
expressed little or no CD81 and that were refractive to infection with cell-free virus, we showed
that the occurrence of viral cell-to-cell transmission is not influenced by the levels of CD81 on
either donor or recipient cells. Thus, our results show that CD81 plays no role in the cell-to-cell
spread of HCVcc and that this mode of transmission is shielded from neutralizing antibodies.
These data suggest that therapeutic interventions targeting the entry of cell-free HCV may not be
sufficient in controlling an ongoing chronic infection, but need to be complemented by additional
strategies aimed at disrupting direct cell-to-cell viral transmission.
INTRODUCTION
Hepatitis C virus (HCV) is a positive-strand RNA virus,
whose entry into host cells depends on the interaction of its
envelope proteins E1 and E2 with several cellular receptors.
In recent years, the mechanisms of HCV entry have been
largely investigated using retrovirus-based pseudoparticles
bearing HCV envelope proteins (HCVpp), and latterly with
the newly developed authentic HCV cell culture infection
(HCVcc) system (Helle & Dubuisson, 2008; von Hahn &
Rice, 2008). Both the HCVpp and HCVcc systems support
a crucial role for CD81 in mediating virus infection. CD81
is a plasma membrane protein containing a small and a
large extracellular loop (LEL), the latter of which mediates
binding to E2. Infectivity assays have shown that it is
necessary but not sufficient for virus entry into hepatocytes
(Helle & Dubuisson, 2008; von Hahn & Rice, 2008). Recent
studies have identified several conserved E2 residues
located within discontinuous regions as essential for E2–
CD81 interaction and virus entry (Drummer et al., 2006;
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Interestingly, some of these residues (W420, Y527, W529,
G530 and D535) also contribute to the epitopes of various
broadly neutralizing antibodies (nAbs) (Keck et al., 2008;
Law et al., 2008; Owsianka et al., 2008; Perotti et al., 2008;
Tarr et al., 2006).
In addition to entry via receptor-mediated endocytosis,
HCV has recently been shown to spread by direct cell-to-
cell transfer. Valli et al. (2006, 2007) provided evidence of
direct virus transfer into HepG2 cells upon co-cultivation
with persistently infected lymphoblastoid B-cells. Similarly,
cell-to-cell transmission of wild-type (WT) HCVcc was
shown to occur upon co-cultivation of infected hepatoma
cells with their naı ¨ve counterparts under subneutralizing
conditions (Timpe et al., 2008). The latter study suggested
that this route of virus transmission may be independent of
CD81. Conversely, a more recent report described a CD81-
deficient cell line that was resistant to infection with
exogenously added HCVcc, and to cell-to-cell transmission
of virus, concluding that CD81 is absolutely required for
this process (Russell et al., 2008).
We aimed to resolve this issue by using HCVcc mutants
defective in CD81 binding and cell entry, and hepatoma-
derived cell lines deficient in CD81 expression. Our results
show that the mutant HCVcc are capable of cell-to-cell
transmission in cultured cells and provide strong evidence
that CD81 is not required for this process.
METHODS
Antibodies. Mouse monoclonal antibody (mAb) AP33, and the
human mAbs CBH-4B and -7, all recognizing HCV E2, and the anti-
NS5A mouse mAb 9E10 have been described previously (Clayton et
al., 2002; Hadlock et al., 2000; Lindenbach et al., 2005). The sheep
antiserum to NS5A was a kind gift from M. Harris (Institute of
Molecular and Cellular Biology, University of Leeds, Leeds, UK). The
production of the rabbit polyclonal anti-E1 antiserum R1233 will be
described elsewhere. The murine leukemia virus (MLV) gag-specific
mAb was obtained from rat hybridoma cells (CRL-1912; ATCC). The
anti-CD81 mAb (clone JS-81) was purchased from BD Pharmingen.
Cell lines. Human hepatoma Huh7 and related cells, and human
epithelial kidney (HEK)-293T cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum.
Huh7-Lunet (Huh7L) cells represent a subclone of Huh7 cells highly
permissive for HCV RNA replication and display a bimodal
expression level of CD81 (Friebe et al., 2005; Koutsoudakis et al.,
2007). Huh7L cells expressing high levels of CD81 (Huh7L-H/EF)
were obtained by stable transfection with pEF1/V5-HisA/CD81
(Koutsoudakis et al., 2007), whereas cells with low endogenous
CD81 expression were derived by sorting the Huh7L cell population
for cells expressing little or no CD81 (Huh7L-N). The Huh7L-N cells
were subsequently subjected to limiting dilution cloning. Individual
subclones, Lunet/CD81N#4 (Huh7L-#4) and Lunet/CD81N#7
(Huh7L-#7), expressing very low or barely detectable levels of
CD81, were identified by flow cytometry.
To generate stable short hairpin RNA (shRNA)-expressing cells,
Huh7.5 cells (Blight et al., 2002) were transduced with VSV-Gpp
packaged shRNA expression vector pLenti-39-U6-EC-EP7, a human
immunodeficiency virus type 1 provirus expressing the shRNA of
interest from an internal U6 promoter and the blasticidin selectable
marker from a second promoter (kind gift from Daniel Boden, The
Aaron Diamond AIDS Research Center, New York, USA)
(MacDonald et al., 2007). Nucleotide sequences expressing shRNA
targeting the CD81 sequence 59-ACCTGCTCTTCGTCTTCAATT-39
or 59-ACCTCAGTGCTCAAGAACA-39 (nt 268–288 or 732–750
relative to the CD81 cDNA sequence, respectively) were cloned into
pLenti-39-U6-EC-EP7 to generate pLenti-39-CD81sh268 or pLenti-39-
CD81sh732. Huh7.5 cells stably expressing these shRNAs were
designated Huh7.5-268 or Huh7.5-732, respectively. The pLenti-39-
irrelevant-shRNA, which is not predicted to target any human or
murine sequences, was used to generate negative-control shRNA cells
(Huh7.5-irrshRNA) (MacDonald et al., 2007). Transduced Huh7.5
cells were selected by using 6 mg blasticidin ml
21 and the surviving
cells were pooled and used in experiments.
Huh7.5-268 cells were complemented for CD81 expression by
transduction with VSV-Gpp packaged lenti-provirus expressing a
green fluorescent protein (GFP)–CD81 fusion in which the sh268
targeted sequence was disrupted by incorporating silent mutations
(shown in lower case, TAttTatTaTTtGTgTTtAAc) by using overlap-
ping PCR. This mutant CD81 open reading frame was cloned in-
frame downstream of the GFP sequence in TRIP–GFP (Zennou et al.,
2000) creating a fusion protein with CD81 (Huh7.5-268–hCD81).
The same was done with the cell line transduced with pLenti-39-
irrelevant-shRNA (Huh7.5-irrshRNA–hCD81). TRIP–GFP-expres-
sing cells were used as negative control. Huh7.5 cells were transduced
at an m.o.i. greater than 10, such that essentially all cells in the
population expressed the transgene (confirmed by FACS analysis,
data not shown).
To use as GFP-expressing recipient cells in cell-to-cell transfer assays,
all Huh7-, Huh7L- and Huh7.5-derived cell lines were transduced
with a retrovirus vector carrying enhanced green fluorescent protein
(EGFP), followed by selection in medium supplemented with 300 mg
G418 ml
21.
HCVpp infection assay. The cDNA sequence encoding the HCV
genotype 2a strain JFH1 (Wakita et al., 2005) aa 132–746 representing
the C terminus of core, E1 and E2 were cloned into the mammalian
expression vector phCMV. Alanine substitution of W529 and D535
was performed by fusion PCR using appropriate primers and the
mutated sequences verified by nucleotide sequencing. The plasmids
expressing the MLV Gag–Pol, and the MLV transfer vector expressing
GFP were gifts from Francois-Loic Cosset (Inserm U758 – Ecole
Normale Supe ´rieure de Lyon, Lyon Cedex 07, France). HCVpp were
produced as described previously (Bartosch et al., 2003; Owsianka et
al., 2005). The medium containing HCVpp was collected, clarified,
filtered through a 0.45 mm pore membrane, and subjected to
ultracentrifugation through a 20% sucrose cushion at 116000 g for
2 h at 4 uC.
Generation of HCVcc virus. The plasmids pJFH1 containing the
full-length cDNA and one lacking E1E2 sequences (pJFH1/DE1E2) of
the HCV genotype 2a strain were a kind gift from Takaji Wakita
(Wakita et al., 2005). The mutant E2 sequences were subcloned from
the phCMV plasmid described above to pJFH1. The Renilla
luciferase-expressing HCVcc, FL-J6/JFH-59C19Rluc2AuUbi, has been
described previously (Tscherne et al., 2006). HCVcc were generated
essentially as described previously (Wakita et al., 2005). Briefly,
linearized plasmids carrying HCVcc genomic cDNA were used as a
template to generate viral genomic RNA by in vitro transcription. Ten
micrograms of this RNA was electroporated into Huh7 cells. At
4 days post-transfection, the culture medium was harvested, filtered
through 0.45 mm pore membrane and used as virus stock in infection
assays. Naı ¨ve Huh7 cells were infected with virus stocks for 3 h and
fixed with methanol for immunofluorescence (IF) assays as described
below or lysed in Trizol LS (Invitrogen) for total RNA extraction.
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HCVcc and viral RNA quantification. Virus particles released from
transfected cells were concentrated by centrifugation through a
sucrose cushion as described above, and then subjected to a 20–50%
(w/w) linear sucrose gradient centrifugation at 116000 g for 16 h at
4 uC. One millilitre fractions were collected and the viral RNA
concentration was determined by absolute quantification by using a
real-time RT-PCR (RT-qPCR) assay. In vitro-transcribed HCV strain
JFH1 genomic RNA of known concentration was used as a standard.
The probe sequence used was 6-FAM-AAAGGCCTTGTGGTACTG-
MGB (Applied Biosystems), and primer sequences were: forward, 59-
TCTGCGGAACCGGTGAGTAC-39 and reverse, 59-GCACTCGCAA-
GCGCCCTATC-39 (Sigma).
Viral RNA levels in infected cells were quantified in a relative RT-
qPCR. Samples were run as a multiplex reaction containing the
primers and FAM probe described above, and a pre-validated human
glyceraldehyde-3-phosphate dehydrogenase endogenous control pri-
mer/probe mix. The values obtained were normalized to WT.
Detection of cell-to-cell transport. To detect cell-to-cell transfer of
HCV, freshly electroporated Huh7 cells were seeded and incubated
for a 24 h period, and then washed with medium to remove residual
RNA before adding the EGFP-expressing recipient cells. The co-
cultured cells were grown to confluency, trypsinized and reseeded on
coverslips for IF analysis or fixed with 1% paraformaldehyde and
permeabilized with 0.1% saponin for FACS analysis. The cells were
stained using sheep anti-NS5A followed by a tetramethyl rhodamine
isothiocyanate (TRITC)-conjugated secondary antibody for IF or the
anti-NS5A mAb 9E10 followed by a phycoerythrin (PE)-conjugated
secondary antibody for FACS analysis.
GNA (Galanthus nivalis antigen) capture assay for E2 analysis.
ELISAs to detect mAb binding to E2 glycoprotein in transfected HEK-
293T andHuh7cells wereperformedessentially asdescribed previously
(Patel et al., 2000). Bound glycoproteins were detected using the anti-
E2 mAbs AP33, CBH-4B or -7, followed by an anti-species IgG–
horseradish peroxidase (HRP) and 3,39,5,59-tetramethylbenzidine
(TMB) substrate. Absorbance values were determined at 450 nm.
Indirect IF. To examine intracellular expression of HCV proteins, cells
on coverslips were fixed in methanol, washed with PBS containing
0.05% Tween-20 (PBS-T) and incubated at room temperature for 1 h
withspecific antibodiestoNS5A. CellswerewashedwithPBS-T, stained
with anti-species IgG conjugated with either fluorescein isothiocyanate
or TRITC (Sigma) for 1 h, washed with PBS-T, and mounted on a glass
slide and examined with a Zeiss Laser Scanning Microscope.
E2–CD81-binding assay. Human CD81-LEL fused to glutathione S-
transferase (GST–CD81) was expressed in Escherichia coli and bound to
glutathione–agarose beads (Sigma). After equilibration with cell lysis
buffer (20 mM Tris pH 7.5, 1 mM EDTA, 150 mM NaCl, 20 mM
iodoacetamide, 1% NP-40), lysates of Huh7 cells electroporated with
viral RNA were added and incubated for 30 min. As a control, an
unrelated GST fusion protein was used as bait. The beads were washed
three times with lysis buffer and the pull-down products analysed by
Western immunoblots as described previously (Owsianka et al., 2005).
RESULTS
Expression and analysis of mutated HCV strain
JFH1 E2
We investigated the functional importance of the con-
served E2 residues W529 and D535 (previously shown to
be critical for HCV genotype 1a E2–CD81 interaction and
HCVpp entry; Owsianka et al., 2006) in the genotype 2a
strain JFH1. The corresponding residues in JFH1 are W531
and D537 (Kato et al., 2001), but we designated them as
W529 and D535 in keeping with the recommendation to
assign absolute amino acid numbering, based on the
reference genotype 1a strain H77 polyprotein (Yanagi et al.,
1997), to the HCV proteins of different genotypes (Kuiken
et al., 2006). The consequence of substituting each of these
residues with alanine was studied initially using the
HCVpp system. Immunoprecipitation using anti-E1 and
anti-E2 antibodies showed that the mutants formed non-
covalent E1E2 heterodimers as efficiently as the WT
proteins in both HCVpp and cell lysates (Fig. 1a and b),
but HCVpp infectivity was completely abrogated (Fig. 1c).
We next introduced the W529A or D535A substitution into
the JFH1 genomic cDNA for analysis in the HCVcc system.
The viral NS5A protein was expressed at comparable levels
in cells electroporated with WT and mutant RNA tran-
scripts, indicating that the mutations in E2 had no apparent
effect on viral RNA replication (Fig. 2a). Furthermore, the
levels of mutant E2 in these cells were similar to that of the
WT glycoprotein, as detected using anti-E2 mAbs recogniz-
ing linear (Clayton et al., 2002) or conformation-dependent
epitopes (Hadlock et al., 2000) (Fig. 2b–d). Thus, the
mutations had no discernible effect on the expression or
overall conformation of E2 in the HCVcc system.
Strain JFH1 E2 residues W529 and D535 are
critical for CD81 binding and virus infectivity but
not for virus particle assembly
To test whether the E2 mutants were interacting with
CD81, we performed a pull-down assay using a GST–CD81
fusion protein and lysates of Huh7 cells electroporated with
viral RNA. Both mutant and WT E2 were expressed in cells
in comparable amounts (Fig. 3a, lanes 1–3). No WT E2
band was detected when an unrelated GST-fusion protein
was used as bait in the pull-down assay (lane 4). With the
GST–CD81 beads, a clear signal for WT but not mutant E2
was observed, indicating that both the W529A and D535A
substitutions in E2 indeed abrogated the interaction
between the JFH1 glycoprotein and CD81 (lanes 5–7).
As the mutations are in a structural protein, we assessed
whether HCVcc particles were assembled and secreted, and
whether they differed from WT in their biophysical
properties. Fractionation of HCVcc over a sucrose gradient
showed that both the mutant and WT viral RNA
sedimented at a density of 1.13–1.14 g ml
21 (Fig. 3b),
which is consistent with that reported previously for WT
HCVcc (Lindenbach et al., 2005; Wakita et al., 2005). We
conclude that alanine substitution of W529 or D535 in the
genotype 2a JFH1 HCVcc has no effect on viral RNA
replication nor on the production of virus particles and
their biophysical properties. We then tested the ability of
these particles to infect naı ¨ve cells. In contrast to the WT
virus-infected cells, no NS5A expression was observed in
J. Witteveldt and others
50 Journal of General Virology 90Fig. 1. Heterodimerization and functional analysis of mutated JFH1 E2. HEK-293T cells co-transfected with MLV packaging and
transfer vectors together with a construct expressing HCV JFH1 WT or mutant E2 were radiolabelled with [
35S]methionine as
described previously (Owsianka et al., 2005). Viral glycoproteins present in (a) the secreted HCVpp and (b) the cell lysates were
immunoprecipitated using anti-E1 antiserum R1233 or the anti-E2 mAb AP33 as shown and the immune complexes analysed by
non-reducing SDS-PAGE. The radiolabelled proteins were visualized using a Bio-Rad Personal FX phosphorimager. The HCVpp
were also subjected to Western immunoblotting using a MLV gag-specific mAb to detect gag proteins (bottom of panel a). The
positions of molecular mass markers in kDa are shown. (c) HCVpp incorporating the WT or mutated JFH1 E2 were used to infect
Huh7 cells. The infectivity, expressed as GFP-positive cells (%), was measured as described in the Methods.
Fig. 2. Characterization of mutant HCVcc. (a) Huh7 cells electroporated with WT or mutant HCVcc RNA were incubated for
4 days after which they were fixed, stained for NS5A and analysed by confocal microscopy. (b–d) Serial dilutions of Huh7 cell
lysates from (a) were analysed for E2 levels by GNA capture ELISA using mouse mAb AP33 that recognizes a linear epitope
(Clayton et al., 2002), or the conformation-dependent human mAbs CBH-7 and -4B (Hadlock et al., 2000). The mean
absorption values with SD bars derived from experiments performed in triplicate are shown. $, WT JFH1; #, JFH1W529A; .,
JFH1D535A.
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qPCR analysis confirmed the absence of viral RNA in
mutant virus-infected cells (data not shown). Thus, in
keeping with our HCVpp results (Fig. 1c), the substitution
W529A or D535A in E2 completely abrogated HCVcc
infectivity.
Mutant virus particles do not enter cells
To find out whether the non-infectivity of the mutants was
due to a block at cell binding or at a post-binding stage,
Huh7 cells were incubated at 4 uC with virus particles for
2 h. Quantification of viral RNA on these cells showed that
both mutant and WT viruses were able to efficiently bind
cells (Fig. 3d). To test for virus entry, cells incubated with
virus particles at 4 uC for 2 h were shifted to 37 uC for 6 h
and then treated with proteinase K to remove any remnant
particles from the cell surface. After this treatment, viral
RNA could be detected in cells incubated with the WT but
not with the mutant virus, which indicates that the failure
of the mutants to infect naı ¨ve cells is due to a defect at a
post-binding step. As a control, cells pre-incubated with
Fig. 3. Alanine substitution of E2 residues W529 or D535 abrogate E2–CD81 interaction and HCVcc infectivity, but not virus
particle assembly and secretion. (a) Lysates of Huh7 cells electroporated with WT or mutant HCVcc RNA were incubated with
GST–CD81 or an irrelevant GST-fusion protein bound to glutathione–agarose beads in a pull-down assay. The resulting
protein complexes (lanes 4–7) as well as the original lysates (lanes 1–3) were subjected to immunoblot using the anti-E2 mAb
AP33. The positions of molecular mass markers in kDa are shown. (b) Sucrose cushion-pelleted HCVcc particles from culture
medium of Huh7 cells electroporated with WT JFH1 ($), JFH1W529A (.) or JFH1D535A (#) were subjected to a 20–50%
sucrose gradient centrifugation, then fractions were collected from the top of the gradient and the viral RNA content was
determined. The sucrose density (h) in each fraction was also measured. (c) Culture medium of cells electroporated with WT or
mutant HCVcc RNA was used to infect naı ¨ve Huh7 cells. Following incubation for 4 days, the cells were fixed and analysed for
NS5A by confocal microscopy. (d) Mutant virus particles bind, but do not enter cells. Huh7 cells were incubated at 4 6C with
sucrose cushion-concentrated virus particles for 2 h. The pre-incubated cells were then split three ways. The first batch of cells
was washed with PBS and lysed for total RNA extraction. The second batch was washed three times, followed by incubation
with 50 mg proteinase K ml
”1 at 4 6C for 1 h with gentle agitation before lysing for RNA extraction. The third batch of cells was
placed in fresh medium after removing the virus inoculum, shifted to 37 6C for 6 h and washed to remove any remaining cell
surface-bound HCV particles before RNA extraction. The relative quantity of viral RNA in each of the total RNA samples was
determined by RT-qPCR.
J. Witteveldt and others
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with proteinase K and then tested for viral RNA. A very low
signal was obtained with all three viruses, demonstrating
that the proteinase K treatment efficiently removed cell-
bound HCVcc particles (Fig. 3d).
Mutant viruses are competent for direct cell-to-
cell spread
There have been conflicting reports on the role of CD81 in
direct cell-to-cell transmission of HCV. Using the HCVcc
mutants described here, we investigated whether CD81 is
necessary for cell-to-cell transmission of HCV in cultured
cells. Huh7 cells electroporated with JFH1W529A or
JFH1D535A RNA were grown for 24 h, then washed and
co-cultured with naı ¨ve Huh7 cells constitutively expressing
EGFP (Huh7–GFP). To maximize the opportunity for cell-
to-cell interactions and virus transfer, the cells were grown
to confluency, trypsinized, reseeded on coverslips and
analysed the next day by IF for NS5A expression. Cells
expressing both EGFP and HCV NS5A would be indicative
of cell-to-cell transmission of virus from the electroporated
Huh7 donor cells to the recipient Huh7–GFP cells. We
observed a small number of cells expressing both EGFP and
NS5A, indicating that both mutants were capable of cell-
to-cell spread in tissue culture (Fig. 4). In contrast, co-
cultivation of Huh7–GFP cells with Huh7 cells electro-
porated with JFH1DE1E2 RNA (lacking the viral E1E2
glycoprotein-encoding sequences) yielded no EGFP/NS5A-
positive cells, suggesting that this mode of virus spread is
E1E2-dependent (Fig. 4).
The ability of the CD81 binding defective viruses to spread
via direct cell-to-cell transmission indicates that CD81 may
not be required in this process. However, a possibility
remains that the interaction between the mutant E2 and
CD81, even though undetectable in our GST–CD81 pull-
down assays, is not completely abrogated. Also, a low
affinity of mutant E2 for CD81 may in part be
compensated by cell-to-cell contact facilitating HCV–
CD81 interactions, thus allowing a low level of entry to
occur. Furthermore, although the CD81-binding mutants
were shown to be non-infectious and no infectious
particles were observed over multiple passages, the
presence of infectious particles arising through comple-
mentary/revertant mutations cannot be excluded.
However, co-cultivation experiments in the presence of a
well-characterized neutralizing anti-CD81 mAb did not
alter the levels of cell-to-cell transmission (Supplementary
Fig. S1a and b available in JGV Online). These findings
were further substantiated by co-cultivation experiments in
the presence of neutralizing anti-E2 antibodies, known to
block E2–CD81 interactions, which also did not affect
levels of cell-to-cell transmission (Supplementary Fig. S1c).
To quantify the levels of cell-to-cell viral transmission, the
co-cultured cells were analysed by flow cytometry. The
level of dually stained cells, and thus cell-to-cell transmis-
sion of JFH1W529A was approximately 0.6% of the total cell
population (i.e. 16% of all NS5A-positive cells) (Fig. 5b,
lower panel). No cell-to-cell transmission was observed
when Huh7 cells electroporated with a viral RNA lacking
E1E2-encoding sequences were co-cultured with Huh7–
GFP cells (Fig. 5a, lower panel), confirming that the viral
glycoproteins are essential for this process. We next tested
the ability of JFH1W529A to spread by cell-to-cell transfer in
two related cell lines, Huh7L and Huh7.5. In keeping with
our data on Huh7 cells, the frequency of cell-to-cell
transmission from Huh7L to Huh7L–GFP or from Huh7.5
to Huh7.5–GFP as the percentage of double-positive cells
of all NS5A-positive cells was 12 and 20%, respectively
(Fig. 5c and d, lower panels).
HCVcc cell-to-cell transmission is not dependent
on CD81 expression
To further confirm the dispensability of CD81 in HCVcc
cell-to-cell transmission, we generated stable Huh7L- and
Fig. 4. Cell-to-cell spread of HCVcc E2 mutants. Huh7 cells
electroporated with WT or mutant JFH1 RNA were co-cultured
with naı ¨ve Huh7–GFP. The cells were fixed in methanol, probed for
NS5A using the anti-NS5A antiserum and anti-sheep IgG-TRITC
conjugate, and examined with a Zeiss Laser Scanning Microscope.
Arrows mark GFP-positive cells expressing NS5A as a result of
virus cell-to-cell transmission.
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(N–GFP, #4–GFP, #7–GFP, 268–GFP and 732–GFP), or
elevated levels of CD81 (N/HE–GFP, 268hCD81–GFP,
irrshRNA–hCD81). We also engineered them to stably
express EGFP to use them as recipients in our cell-to-cell
transfer assay. The EGFP-expressing cell lines were first
tested for susceptibility to HCVcc infection using the FL-
J6/JFH-59C19Rluc2AuUbi virus that expresses luciferase
(Tscherne et al., 2006). As expected, there was a clear
correlation between CD81 expression and virus infectivity
(Fig. 6a and b). Lines expressing low levels of CD81 were
refractive to infection and showed only background levels
of luciferase activity, in keeping with previous studies
which show that productive HCVcc infection requires a
minimal level of CD81 expression (Koutsoudakis et al.,
2007).
We next investigated the cell-to-cell transmission of
JFH1W529A HCVcc in these cell lines. Parent Huh7L and
Huh7.5 cell lines electroporated with JFH1W529A RNA were
co-cultured with their corresponding (EGFP-expressing)
CD81-deficient or CD81-overexpressing counterparts and
analysed by flow cytometry. We found that the CD81 status
of the recipient cells had no influence on the frequency of
cell-to-cell virus transmission (Fig. 6c and d).
The donor cells used in the above experiments express
normal levels of CD81, which may somehow facilitate virus
transmission into the recipient cells via a receptor-
dependent route. To exclude this possibility, co-cultivation
experiments using the CD81-negative cell line Huh7L-#4
as both donor and recipient were performed. As a control,
the parental Huh7L cells were included. In all donor/
recipient combinations no significant difference in cell-to-
cell transmission was observed (one-way ANOVA, P.0.10)
(Fig. 7), which rules out any possible contribution of
CD81, present on either donor or recipient cells, in this
process. Taken together, our data lead us to conclude that
cell-to-cell transmission of HCVcc in culture does not
involve CD81.
Recipient to donor cell ratios determine levels of
cell-to-cell transport
To get a better understanding of the kinetics underlying
cell-to-cell transport, various ratios of recipient to donor
cells were used. Huh7L#4 cells electroporated with
JFH1W529A were co-cultured with the same cells expressing
EGFP at different seeding ratios and the levels of cell-to-cell
transport were determined by FACS. Interestingly, an
increase in cell-to-cell transport was observed as the
proportion of recipient cells was increased, reaching a
maximum at an initial recipient to donor ratio of 2:1 (Fig.
8). However, the number of donor cells became a limiting
factor at a ratio of 4:1. These results show that there is a
clear correlation between the number of recipient cells and
the frequency of cell-to-cell transmission.
DISCUSSION
HCV, like other enveloped viruses, enters its target cells
through a complex and not fully understood process
involving virus interaction with several receptors and co-
receptors. That said, the importance of the E2–CD81
interaction in HCV entry has been extensively explored.
Based on our previous study with genotype 1a HCVpp
(Owsianka et al., 2006), we generated genotype 2a HCVcc
mutant viruses defective in CD81 binding. The mutant
particles bound host cells as efficiently as the WT virus, but
failed to enter cells, suggesting that the defect lies at a post-
binding stage, which is in keeping with the role of CD81 as
a co-receptor (Cormier et al., 2004). Together, our results
confirm the critical role of the conserved E2 residues W529
and D535 in HCV infection, and provide a possible target
for the future development of small-molecule entry
inhibitors active against diverse HCV genotypes.
Fig. 5. Quantitations of cell-to-cell spread of mutant HCVcc using
flow cytometry. Huh7 cells electroporated with (a) JFH1DE1E2 or
(b) JFH1W529A RNA were co-cultured with Huh7–GFP cells.
Following incubation, cells were fixed and probed with the anti-
NS5A mAb 9E10 and analysed by FACS. Similar analysis was
performed using (c) Huh7L or (d) Huh7.5 cells electroporated with
JFH1W529A RNA. The upper left quadrant of each dot plot shows
the percentage of NS5A-expressing donor cells, and the upper
right quadrant shows the percentage of recipient cells co-
expressing EGFP and NS5A. The populations of untransfected
and uninfected cells are shown in the lower left and lower right
quadrants, respectively. The upper dot plot in each panel
represents cells that have been probed with only the PE-
conjugated secondary antibody to serve as negative control.
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to-cell transmission in the presence of virus nAbs (Timpe
et al., 2008). We reasoned that using entry-defective cell-
free mutant viruses without neutralizing agents would
provide a more robust system to gain insights into the
mechanism governing cell-to-cell transmission. Since the
mutants described in this study are non-infectious, but
otherwise comparable to the WT virus with respect to their
replicative capacity and biophysical properties, they are
ideally suited for this purpose. Co-cultivation of mutant-
transfected cells with EGFP-expressing recipients resulted
in a low level of cell-to-cell spread in culture. We further
showed that HCV glycoproteins are essential for this mode
of virus transmission.
Even though the interaction between mutant E2 and CD81
was undetectable in our assay, a low affinity HCV–CD81
interaction, either direct or facilitated by cell-to-cell
contact, could account for the infected recipient cells.
However, co-cultivation experiments in the presence of
antibodies blocking the E2–CD81 interaction did not
inhibit cell-to-cell transmission. To further establish the
dispensability of CD81 in this entry process, we used
several cell lines expressing either low or barely detectable
levels of CD81. A clear correlation between the CD81
expression levels and susceptibility to WT virus infection
was observed in them. We identified several cell lines that
were refractive to infection with cell-free virus. In all these
cell lines, whether expressing CD81 or not, and when used
Fig. 6. Cell-free virus infection, but not cell-to-cell transmission, correlates with CD81 expression. (a) Huh7L- or (b) Huh7.5-
derived cell lines expressing varying levels of CD81 were infected with the luciferase-expressing virus, FL-J6/JFH-
59C19Rluc2AuUbi. At 3 days p.i., infectivity was measured by determining intracellular luciferase activity, which is presented as
relative light units (black bars). In parallel, the relative levels of CD81 surface expression, presented as mean fluorescence
intensity (grey bars), were determined by FACS using an anti-CD81 mAb and PE-conjugated secondary antibody. (c) Huh7L or
(d) Huh7.5 cells electroporated with JFH1W529A RNA were co-cultured with their corresponding Huh7L- or Huh7.5-derived
CD81 variant cell lines. Following incubation for 4 days, cells were fixed and analysed by FACS. The frequency of cell-to-cell
spread is presented as double-positive (NS5A/GFP) of all NS5A-positive cells (%) (black bars). The relative levels of CD81
expression (as derived in a and b above) in each cell line are plotted side by side (grey bars).
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sion of the mutant virus occurred at comparable levels.
Together, these results unequivocally show that CD81 plays
no role in the cell-to-cell spread of HCVcc.
Our results show that cell-to-cell transmission occurs at a
relatively low frequency, generally requiring multiple HCV-
positive donor cells to infect a single recipient cell. In
contrast, the Timpe et al. (2008) study indicates one donor
cell infecting up to five recipient cells, effectively amount-
ing to cell-to-cell transmission being the predominant
mode of virus spread in cell culture. If so, any replication-
competent non-infectious virus capable of cell-to-cell
transmission is expected to be stably maintained in cell
culture. However, cells replicating our E2 mutant virus
genomes were readily lost upon passaging. There are
several possible explanations for these apparent discrep-
ancies. Timpe et al. (2008) used WT virus-infected donor
cells and concentrations of antibodies neutralizing less than
100% of infection via the cell-free, CD81-mediated route.
Also, the dye they used to label recipient cells [59-
chloromethylfluorescein diacetate (CMFDA)] is rapidly
transported via gap junctions to adjacent cells (Barhoumi
et al., 1993; Bazou et al., 2006; He et al., 2007). This
diffusion from the labelled recipient to the infected donor
cells would result in gross overestimation of cell-to-cell
transmission levels. Their study found HepG2, HeLa and
HEK-293T cells supporting reduced levels of cell-to-cell
transmission. It is likely that the CMFDA diffusion in these
cells is impaired as they, unlike Huh7, contain low
numbers of gap junctions or none at all (Carruba et al.,
2004; Clayton et al., 2005; de Feijter-Rupp et al., 1998;
Stong et al., 2006). In our co-culture system, we found no
evidence for passive diffusion of EGFP from recipient to
donor cells (Fig. 5a).
A recent paper reported a CD81-deficient cell line, S29, in
which cell-to-cell transmission of an infectious HCVcc was
not observed, leading to the suggestion that CD81 is
absolutely required for this process (Russell et al., 2008).
This observation conflicts with our data obtained using
various independently generated CD81-deficient lines.
Without direct comparison of the cell lines it is difficult
to speculate, but the possible reasons for this anomaly may
be a suboptimal donor to recipient cell ratio, or the lack of
host factor(s) other than CD81 in this line. In this respect,
S29 may prove a very useful cell line to identify host factors
necessary for HCV cell-to-cell transmission.
HCV successfully evades the host-immune response despite
the presence of nAbs. Direct cell-to-cell spread may be one
way by which the virus is able to escape from nAbs and
persist in vivo. As the mechanisms governing HCV cell-to-
cell transmission are unknown, comparison with better-
studied RNA viruses may provide some clues. Examples of
cell-to-cell spread can be found in a number of viruses
including rabies virus, human T-cell leukemia virus 1 and
human immunodeficiency virus type 1. In all of these, viral
spread via direct cell-to-cell transmission is protected from
nAbs. In retroviruses, the induction of synapse-like
structures facilitating cell-to-cell spread is triggered by
the interaction of the viral glycoprotein (env) with specific
host receptors. Blocking the env–cell receptor interaction
abolishes cell-to-cell transmission (Jolly & Sattentau, 2004;
Fig. 7. Expression of CD81, on either donor or recipient cells, is
not necessary for cell-to-cell virus spread. Co-cultivations of
different combinations of CD81-negative (Huh7L-#4) and
-positive (Huh7L) donor cells (electroporated with JFH1W529A
RNA) and CD81-negative (Huh7L-#4) and -positive (Huh7L)
recipient cells as shown were fixed and analysed by FACS. The
frequency of cell-to-cell spread is presented as double-positive
(NS5A/GFP) of all NS5A-positive cells (%).
Fig. 8. Donor to recipient cell ratio determines levels of cell-to-cell
transport. JFH1W529A RNA-electroporated donor Huh7L#4 cells
were co-cultured with Huh7L#4–GFP cells at different initial
seeding ratios as shown, and incubated for 4 days. The cells were
fixed and analysed by flow cytometry, and the relative numbers of
recipient (dark grey) and donor cells (light grey) as well as the rate
of cell-to-cell transmission (broken line) were determined. The final
ratio of the cells following incubation is presented as total cells
(%), whereas the frequency of cell-to-cell transfer is shown as
NS5A-positive cells of all GFP-positive cells (%).
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teins are essential for HCV cell-to-cell spread, but their
interaction with CD81 is dispensable, so other receptors
may be involved. It remains to be seen whether synapse-
like structures govern this process in HCV. A considerable
effort is currently being directed towards developing
inhibitors of cell-free virus entry. In this respect, inhibitors
targeting the HCV–CD81 interaction might be most
effective in the transplant setting in preventing infection
of the new organ by blood-borne virus, but less so in the
context of ongoing chronic infection where direct cell-to-
cell spread of the virus would remain unchecked.
Therefore, for effective prevention and spread of infection,
the cell-to-cell mode of virus transmission must also be
considered as a target for antiviral development. The
experimental systems described here will be useful for
elucidating the processes involved in this mode of infection
and their contribution to virus persistence and immune
escape. Such information will prove important in the
future design of inhibitors targeting HCV cell-to-cell
transmission.
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